Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 8;12:2040622321997259. doi: 10.1177/2040622321997259

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2021

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 5. — KDM4C regulates miR-328-3p/CCND2 through MALAT1 leading to Ara-C resistance in AML. (a) RT-qPCR to detect the expression of KDM4C, MALAT1, miR-328-3p, and CCND2 after knockdown of KDM4C or overexpression of CCND2 in HL-60/A cells, *p < 0.05 compared with sh-NC + oe-NC, ^#p < 0.05 compared with sh-KDM4C + oe-NC. (b) Western blot to detect the expression of KDM4C and CCND2 after knockdown of KDM4C and overexpression of CCND2 in HL-60/A cells, *p < 0.05 compared with sh-NC + oe-NC, ^#p < 0.05 compared with sh-KDM4C + oe-NC. (c) MTT assay to analyze the viability of HL-60/A cells after knockdown of KDM4C and overexpression of CCND2 in HL-60/A cells, *p < 0.05 compared with HL-60/sh-KDM4C + oe-NC, ^#p < 0.05 compared with sh-NC + oe-NC/sh-KDM4C + oe-CCND2. (d) Flow cytometry to analyze the cell cycle of HL-60 and HL-60/A cells, *p < 0.05 compared with sh-NC + oe-NC, ^#p < 0.05 compared with sh-NC + oe-CCND2. Experiments were repeated three times. Data among multiple groups were analyzed by one-way analysis of variance.

AML, acute myeloid leukemia; Ara-C, cytarabine; G1, G1-phase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; NC, negative control; oe, overexpression; RT-qPCR, real-time quantitative polymerase chain reaction; S, S-phase; sh, short hairpin; MTT, 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; miR-328-3p, microRNA-328-3p.